Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).

@article{Valencia2007EfficacyAS,
  title={Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).},
  author={Rafael Valencia and Matthew J Price and Neil S Sawhney and Steve Seung-Young Lee and Garrett B Wong and Raghava R Gollapudi and Michelle Banares and Richard A. Schatz and Paul S. Teirstein},
  journal={The American journal of cardiology},
  year={2007},
  volume={100 7},
  pages={1099-102}
}
Adjunctive glycoprotein IIb/IIIa inhibition decreases ischemic events after percutaneous coronary intervention (PCI) but is associated with increased bleeding. We hypothesized that maximal antiplatelet therapy with aspirin, a thienopyridine, and a glycoprotein IIb/IIIa inhibitor without unfractionated heparin (UFH) would result in fewer bleeding complications and maintain efficacy in elective PCI. A total of 159 patients undergoing elective PCI were randomized to intraprocedural eptifibatide… CONTINUE READING